{'fraction_non_alphanumeric': 0.06756756756756757, 'fraction_numerical': 0.025525525525525526, 'mean_word_length': 4.379032258064516, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Development and Therapeutic Uses of Topical 5% Idoxuridine (IDU)

5-IODO-21_DEOXYURIDINE (J.D. U.) was first synthesized by Prusoff (1959) and 5 years later was shown to have highly significant activity in vitro against varicella-zoster virus (Rapp & Vanderslice, 1964). Despite this, a further decade elapsed before a pharmaceutical company felt that sufficient objective evidence had accumulated to justify producing an J.D.U. skin preparation for general use5 per cent J.D. U. in 100 per cent dimethyl sulphoxide (D.M.S.O.)-Herpid (W. B. Pharmaceuticals). In this paper the development, pharmacology and therapeutic uses of topical LD.U. in D.M.S.O. are reviewed.